{'fraction_non_alphanumeric': 0.030857142857142857, 'fraction_numerical': 0.024, 'mean_word_length': 5.3478260869565215, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prolactin response to dopamine synthesis inhibition using monoiodotyrosine in subjects on oral contraceptives and patients with pathological hyperprolactinemia.

Monoiodotyrosine (MIT), a specific inhibitor of central dopamine synthesis, has been used to study dopaminemediated inhibitory control of PRL release in 10 normal women, 19 women on oral contraceptive steroids (OC), and 14 women with pathological hyperprolactinemia to test the hypothesis that while the mild hyperprolactinemia in OC subjects is under dopaminergic control, there is a loss of inhibitory control in subjects with pathological hyperprolactinemia. Of these latter patients, 6 had normal pituitary fossa on x-rays, and 8 had unequivocal radiological evidence of a pituitary tumor.Subjects on OC had a significantly higher mean basal PRL level (353 ± 34 vs. 280 ± 26 mIU/liter; P 400 mIU/liter; n =...